SCHEMBL6315633

SCHEMBL6315633

COc1ccc(OC)c(C(=O)C2CC2c2ccc(C)c(OOP(=O)(O)O)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 3/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KDM1A O60341 1/20 0.36
APP P05067 1/20 0.36
SLC9A1 P19634 1/20 0.36
ALDH1A1 P00352 5/20 0.36
ABCG2 Q9UNQ0 1/20 0.35
POLB P06746 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
EGFR P00533 1/20 0.35
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316452 0.94 MAPT (0.39) MAPTL3MBTL1LMNAKDM4EMEN1
SCHEMBL6314453 0.93 MAPT (0.43) MAPTL3MBTL1LMNAKDM4EMEN1
SCHEMBL6321011 0.92 MAPT (0.36) MAPTL3MBTL1LMNAKDM4EMEN1
SCHEMBL6316369 0.91 MAPT (0.37) MAPTL3MBTL1LMNAKDM4EMEN1
SCHEMBL6313897 0.90 KDM1A (0.38) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL6315434 0.90 MAPT (0.41) MAPTL3MBTL1LMNAKDM4EMEN1
SCHEMBL6315215 0.87 MAPT (0.39) MAPTL3MBTL1LMNAKDM4EMEN1
SCHEMBL6315313 0.87 MAPT (0.41) MAPTL3MBTL1LMNAKDM4EMEN1
SCHEMBL6315408 0.84 MAPT (0.38) MAPTL3MBTL1LMNAKDM4EMEN1
SCHEMBL6315331 0.84 MAPT (0.38) MAPTL3MBTL1LMNAKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887904-B2 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-05-03 US disclosed
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885L3MBTL1 3439/4885LMNA 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.